GlassScriptPhysician profile
Crystal A Bujold
NPI 1437482171
$8,997.86
in general payments reported to CMS, 2019-2025
41 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,877 · 2020: $1,612 · 2021: $1,219 · 2022: $1,241 · 2023: $1,713 · 2024: $863 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,048.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,085.99 | 2019-2024 | Gallant, Aveir, Thoratec Heartmate 3 Lvas Implant Kit |
| Boston Scientific Corporation | $972.78 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $843.02 | 2019-2025 | Lifevest |
| Amgen INC. | $840.31 | 2019-2024 | Repatha |
| Heartflow, INC. | $751.16 | 2019-2024 | Ffrct |
| Novartis Pharmaceuticals Corporation | $703.50 | 2019-2025 | |
| Impulse Dynamics (USA) INC. | $541.97 | 2022-2025 | Optimizer |
| Sanofi-Aventis U.S. LLC | $482.90 | 2019-2024 | |
| Amarin Pharma, INC. | $415.76 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $350.45 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $334.70 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $211.79 | 2021-2025 | Verquvo |
| Itamar Medical INC | $208.21 | 2021-2024 | Watchpatone |
| Pfizer INC. | $179.21 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.99 | 2021-2023 | Jardiance |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $116.57 | 2022-2024 | Camzyos, Eliquis |
| Novo Nordisk INC | $78.80 | 2021-2025 | Wegovy |
| Medtronic, INC. | $71.89 | 2022-2023 | Corevalve Evolut R |
| Edwards Lifesciences Corporation | $61.92 | 2019-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Kiniksa Pharmaceuticals International, Plc | $59.84 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $54.26 | 2020-2024 | Nexletol |
| Baxter Healthcare | $48.43 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Stryker Corporation | $45.30 | 2025 | Flowtriever |
| Cvrx, INC. | $44.96 | 2023-2024 | Barostim Neo System |
| Braemar Manufacturing, LLC | $40.26 | 2019 | |
| Tactile Systems Technology INC | $38.57 | 2019-2021 | |
| Abiomed | $38.23 | 2025 | |
| Arbor Pharmaceuticals, INC. | $36.78 | 2020 | |
| Cardinal Health 200 LLC | $24.74 | 2019 | |
| Lantheus Medical Imaging, INC. | $24.01 | 2025 | |
| Inogen, INC. | $22.00 | 2025 | |
| Vifor Pharma, INC. | $20.62 | 2019 | |
| Inspire Medical Systems, INC. | $16.04 | 2023 | Inspire |
| Kiniksa Pharmaceuticals, LTD. | $15.68 | 2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $15.15 | 2023 | Inpefa |
| Scpharmaceuticals INC. | $14.98 | 2023 | |
| Irhythm Technologies, INC. | $14.88 | 2019 | |
| Gilead Sciences, INC. | $14.13 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.81 | 2019 | |
| G Medical Diagnostic Services, INC. | $13.35 | 2024 | Cardiac Monitoring Suite |
| Allergan, INC. | $12.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Bujold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.